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Network modelingHedgehog interacting protein (HHIP) was implicated in chronic obstructive pulmonary disease (COPD) by
genome-wide association studies (GWAS). However, it remains unclear how HHIP contributes to COPD
pathogenesis. To identify genes regulated by HHIP, we performed gene expression microarray analysis in
a human bronchial epithelial cell line (Beas-2B) stably infected with HHIP shRNAs. HHIP silencing led to
differential expression of 296 genes; enrichment for variants nominally associated with COPD was found.
Eighteen of the differentially expressed genes were validated by real-time PCR in Beas-2B cells. Seven of 11
validated genes tested in human COPD and control lung tissues demonstrated signiﬁcant gene expression
differences. Functional annotation indicated enrichment for extracellular matrix and cell growth genes.
Network modeling demonstrated that the extracellular matrix and cell proliferation genes inﬂuenced by
HHIP tended to be interconnected. Thus, we identiﬁed potential HHIP targets in human bronchial epithelial
cells that may contribute to COPD pathogenesis.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Chronic obstructive pulmonary disease (COPD), the third leading
cause of death in the U.S. [1], is a complex disease strongly inﬂuenced
by cigarette smoking and genetic predisposition [2,3] COPD is charac-
terized by emphysematous destruction of the alveoli and thickening of
the airway walls in response to chronic exposure to cigarette smoke
(CS). While the emphysematous destruction of the lung parenchymatwork Medicine, Department
rvard Medical School, Boston,
u (X. Zhou),
rights reserved.probably results from the cytotoxic and pro-inﬂammatory activities
of CS, the pathogenic mechanisms of the disease remain to be fully
deﬁned [4]. It has been shown that smoke-induced cell apoptosis
and autophagy are likely to be important causes for lung injury during
COPD development; imbalance of proteinases and proteinase inhibi-
tors as well as abnormal tissue repair are other mechanisms likely in-
volved in the pathogenesis of COPD [5].
Genome-wide association studies (GWAS) of COPD have provided
compelling evidence for a disease susceptibility locus on chromosome
4q31 [6,7]. This locus has been signiﬁcantly associatedwith lung func-
tion in the general population [8,9] as well as with COPD [10,11]. Our
previous work has identiﬁed the gene encoding hedgehog interacting
protein (HHIP) as the causative gene for this highly replicated genetic
associationwith COPD susceptibility [12]. Speciﬁcally, we have shown
264 X. Zhou et al. / Genomics 101 (2013) 263–272that SNPs upstream of the HHIP gene modulate expression of HHIP,
implicating reduced HHIP gene expression in the pathogenesis of
COPD [12]. However, the biological mechanisms by which HHIP inﬂu-
ences COPD susceptibility have not been determined.
HHIP is a cellular membrane protein that directly binds to Sonic
Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog
(DHH), which trigger the hedgehog signaling pathway by binding to
theirmembrane receptor, PTCH1. By competingwith PTCH1 for binding
of hedgehog ligands, Hhip negatively regulates the hedgehog pathway,
a crucial pathway for the development of the lungs and other organs
[13–15].
To study the biological pathways connecting HHIP to COPD path-
ogenesis, we determined the effect of HHIP knock-down through
lentivirus-based shRNAs on gene expression in the bronchial epithe-
lial cell line Beas-2B, which has detectable expression of HHIP at a
relatively higher level than primary human airway epithelial cells
(data not shown). Gene expression differences detected by expres-
sion array were validated by RT-PCR in Beas-2B and normal human
bronchial epithelial cells (NHBE). In these systems, we evaluated the
activity of the canonical Hedgehog pathway as well as other novel bio-
logical pathways identiﬁed by gene expression array analysis.
2. Results
2.1. Expression proﬁling in HHIP depleted Beas-2B cells
To identify the full range of cellular targets of HHIP in human bron-
chial epithelial cells, we performed expression microarray analysis in
Beas-2B cells with and without knock-down of HHIP by stable infec-
tion with lentivirus-based shRNAs targeting HHIP. To limit possible
off-target effects of the shRNAs, four different HHIP shRNAs were
used, with up to four replicates for each shRNA (Fig. 1B). Efﬁciency
of HHIP knock-down was shown by at least 70% reduction in HHIP
mRNA in Beas-2B cells after infection with HHIP shRNAs compared to
cells infected with non-targeting control shRNA (NT) (data not shown).
Since there is no consensus in the literature regarding the optimal
analytical approach for batch effect analysis of gene expression array
data, two methods were used. Surrogate variable analysis [16] and
its modiﬁcation, independent surrogate variable analysis (iSVA) [17]
coupled with the linear regression models with an empirical Bayes
shrinkage method (limma), found 317 gene probes (representing 300
unique genes) and 469 gene probes (442 genes) respectively, to be
differentially expressed (p adjusted b0.05) in HHIP shRNA-infected
Beas-2B cells compared to non-targeted shRNA-infected control cells.
Of note, 296 genes were identiﬁed as showing differential gene expres-
sion by both analysis methods (Fig. 1A). Fig. 1B depicts the differential
gene expression pattern for different biological and technical replicatesFig. 1. Gene expression proﬁling analysis in Beas-2B cells stably infected with HHIP shRNAs. A
SVA. B. Expression heat map of 296 differentially expressed genes (columns) (p adjusted b0.
nical replicate; NT shRNA: non-targeting shRNA control; shRNA: HHIP-targeting shRNA.with and without HHIP silencing with four individual HHIP-targeted
shRNAs, showing that the effect of HHIP knock-down on gene expres-
sion is consistently greater than technical batch effects. The top 20 dif-
ferentially expressed genes identiﬁed by iSVA analysis are shown in
Supplemental Table 3. As expected, HHIP ranks ﬁrst on this list. Protein
level reductions of HHIP caused by shRNAs were conﬁrmed byWestern
Blot (Supplemental Fig. 1A).
2.2. Genetic association analysis of differentially expressed genes
To assess the biological importance of these differential gene expres-
sion signals, we evaluated the affected genes for common variant asso-
ciations with COPD based on our previously published genome-wide
association study of four cohorts: The National Emphysema Treatment
Trial/Normative Aging Study, GenKOLS, ECLIPSE, and COPDGene (ﬁrst
1000 subjects) [18].
Among the 296 differentially expressed genes after HHIP silencing
(including the HHIP genic region but not the COPD GWAS region up-
stream from the HHIP gene), 271 were located on autosomes and
harbored high-quality imputed or genotyped SNPs within a window
of 5 kb upstream and 1 kb downstream from the transcribed gene
boundaries. One of the 271 genes, RAB4B is located within the chro-
mosome 19 GWAS region shown to be strongly associated with
COPD. While no other SNPs located within the 271 genes showed an
association with COPD that reached genome-wide signiﬁcance after
a conservative Bonferroni correction within this subset, 115 genes
contained at least one SNP showing association with COPD with
a nominal P value of b 0.05. Based on the method by Lipman and
colleagues [19], these results are consistent with a signiﬁcant enrich-
ment in low P-values (P = 0.02). A histogram plot of LD-pruned
p-values used for the Lipman analysis demonstrated the enrichment
of lower p values (Supplemental Fig. 2), supporting a role of these
differentially expressed genes in COPD pathogenesis.
2.3. Extracellular matrix genes are differentially expressed by
HHIP silencing
Next, we evaluated enrichment of the 296 genes differentially
expressed after HHIP silencing in Gene Ontology (GO) biological pro-
cesses, using DAVID [20] functional annotation analysis (http://david.
abcc.ncifcrf.gov/home.jsp) and GeneMANIA (http://www.genemania.
org/) [21]. Both found signiﬁcant enrichment (P b 0.01, using DAVID
or GeneMANIA) of genes involved in extracellular matrix remodeling
(ECM, Table 1). Based on these pathway analysis results, we used
SYBR-green based RT-PCR analysis to attempt to validate differential
expression of 18 ECM-related genes in Beas-2B cells infected with
three HHIP shRNAs or one control shRNA (Table 2).. Venn diagram showing the number of differentially expressed genes based on iSVA or
05). Each row represents a separate sample (array). Bio: biological replicate; tech: tech-
Table 1
DAVID and GeneMANIA functional annotation clusters for genes regulated by HHIP.
DAVID
Clusters Enrichment score Top GO term Top term Gene count
Fold enrichment P value
1 2.12 GO:0031012 ~ extracellular matrix 2.93 b0.001 14
2 1.75 GO:0047115 ~ trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity 50.45 0.0013 4
3 1.74 GO:0042612 ~ MHC class I protein complex 12.89 b0.001 5
GeneMANIA
Clusters GO annotation FDR Coverage query genes
1 Extracellular matrix 1.82E−04 15/178
2 Proteinaceous extracellular matrix 1.82E−04 12/105
3 DNA conformation change 4.86E−04 11/97
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mental Materials and method section), we found that SYBR-green
RT-PCR expression analysis conﬁrmed the microarray results for
seven genes, demonstrating signiﬁcantly (P b 0.01) increased (FBLN7,
SERPING1, RECK, TULP3) or decreased (SERPINB7,WNT5B, SDC1) mRNA
levels following HHIP silencing in RT-PCR (Table 2). For one gene,
NTN4 (Netrin 4), SYBR-green RT-PCR results contradicted the microar-
ray results. For the remaining ten genes, expression changes measured
by SYBR-green RT-PCR did not reach statistical signiﬁcance, although
a trend was noted for PI3 (P = 0.077). Furthermore, TaqMan-based
RT-PCR conﬁrmed the signiﬁcant or near-signiﬁcant SYBR-green
based RT-PCR results, except for NTN4, which showed no statistically
signiﬁcant expression changes (Fig. 2). Similar results were obtained
when TBP was used as an additional reference gene (data not shown).
2.4. Hedgehog pathway activity lacks signiﬁcant changes in HHIP silenced
Beas-2B cells
HHIP has been shown to inhibit the Hedgehog pathway by com-
petitively binding to three Hedgehog morphogens (SHH, IHH and
DHH) during development [13]. Surprisingly, we did not observe a
signiﬁcant enrichment of canonical Hedgehog pathway members
other than HHIP among genes that were found to be differentially
expressed by microarray analysis after HHIP knockdown. To furtherTable 2
Effect of HHIP knock-down on expression of selected ECM genes, as measured by microarr
Gene symbol Gene name
OLFML2 Olfactomedin-like 2A
TIMP1 TIMP metallopeptidase inhibitor 1
EFEMP2 EGF-containing ﬁbulin-like extracellular matrix protein 2
SPARC Secreted protein, acidic, cysteine-rich (osteonectin)
BGN Biglycan
NTN4 Netrin 4
COL6A2 Collagen type VI, alpha2
GSN Gelsolin
ECM1 Extracellular matrix protein 1
FBLN7 Fibulin 7
SERPING1 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
PI3 Peptidase inhibitor 3, skin-derived
RECK Reversion-inducing-cysteine-rich protein with kazal motifs
TULP3 Tubby like protein 3
SERPINB7 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), memb
WNT5B Wingless-type MMTV integration site family, member 5B
COL13A1 Collagen, type XIII, alpha 1
SDC1 Syndecan 1
a Moderated t-test statistic testing for the hypothesis that a gene probe is differentially
2 estimated independent surrogate variables (iSVA).
b Mean and standard error of mean (sem) of log2 fold change of hairpins versus controls
c p-value for testing if a gene probe is differentially expressed between HHIP hairpins and
signiﬁcantly differentially expressed genes validated by RT-PCR, which were highlighted inexplore the Hedgehog pathway activity in Beas-2B cells with HHIP
silencing, we used TaqMan based qPCR to measure the expression of
ﬁve genes coding for critical components of the canonical Hedgehog
pathway (SHH, PTCH1, GLI1, GLI2, GLI3, IHH, and DHH [22]) in Beas-2B
cells stably infected with two of the HHIP shRNAs that were used in
the microarray analysis.
No statistically signiﬁcant expression changes were detected for
PTCH1 or GLI3, and SHH expression was under the detection limit
in Beas-2B cells (Supplemental Fig. 1B); this low expression level
of SHH in airway cells was conﬁrmed in primary small airway ep-
ithelial cells (data not shown). GLI1 demonstrated increased ex-
pression with HHIP shRNAs but was still expressed at a relatively
low level. In addition, GLI2, previously reported to regulate cell
proliferation during lung development [23], demonstrated a statis-
tically signiﬁcant reduction of 20–30% in expression after HHIP
knock-down with any of the three HHIP shRNAs (Supplemental Fig.
1B). Two other Hedgehog pathway ligands, IHH and DHH, were also
barely detected in Beas-2B cells by qPCR at baseline and after HHIP
silencing (data not shown).
These qPCR data indicate that, HHIP silencing by shRNAs had
a limited effect on canonical Hedgehog pathway members in our
current experimental settings. Hence, these minimal changes of
the canonical Hedgehog pathway may not explain all of the other
gene expression changes that we observed. These results raised theay and SYBR-green based RT-PCR.
Microarray RT-PCR
Statisticsa Adjusted p-value Meanb SEMb p-valuec
4.63 0.02 1.22 0.11 0.213
4.21 0.04 1.01 0.05 0.96
4.94 0.017 1.16 0.11 0.45
4.39 0.03 0.92 0.11 0.44
4.63 0.02 1.31 0.24 0.21
4.01 0.049 0.58 0.08 0.0016
5.25 .0.013 1.13 0.06 0.19
5.95 0.006 1.37 0.14 0.1
4.68 0.02 1.39 0.14 0.095
5.78 0.007 2.07 0.21 b0.001
5.60 0.009 4.35 1.88 0.0039
4.19 0.039 3.50 1.18 0.077
6.12 0.005 2.01 0.17 b0.001
6.56 0.004 1.47 0.07 b0.001
er 7 −5.33 0.012 0.20 0.03 b0.001
−5.18 0.014 0.34 0.07 b0.001
−5.14 0.014 0.59 0.09 0.0249
−4.56 0.026 0.50 0.11 b0.001
expressed between HHIP hairpins arrays and control hairpin arrays adjusting for the
.
NT controls based on linear mixed effects models. Genes with p b 0.01 were regarded as
bold.
Fig. 2. Signiﬁcantly increased (A) and decreased (B) expression (**, p b 0.01) of
HHIP target genes associated with extracellular matrix (ECM) after HHIP silencing
in Beas-2B cells, as measured by TaqMan assay-based RT-PCR. Three different
HHIP-targeted shRNAs were used for knock-down. Relative expression values were
calculated as described in Materials and methods and represent means ± standard
errors from two independent shRNA infections.
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silencing HHIP.
2.5. Cell proliferation-related genes have reduced gene expression upon
HHIP silencing
Ten differentially expressed genes, including two additional
genes identiﬁed by the iSVA analysis method [BDNF (brain-derived
neurotrophic factor) and BTG2 (B-cell translocation gene 2)], associ-
ated with cell growth were chosen for further validation by TaqMan
based RT-PCR in Beas-2B cells (Fig. 3A). Two cell-cycle related
genes, CCND1, encoding Cyclin D1, and G0S2 (G0/G1 switch regulato-
ry protein 2) demonstrated more than 50% reduced expression by
HHIP shRNAs in Beas-2B cells.
Other signiﬁcantly decreased genes include FGF2 (ﬁbroblast
growth factor 2), BIRC5 (baculoviral IAP repeat containing 5), TGM2
(transglutaminase 2), CREB3L2 (cAMP responsive element binding
protein 3-like 2), and ATF5 (activating transcription factor 5), which
are all known to promote cell growth and/or survival ([24–27]), as
well as LETM1 (leucine zipper-EF-hand containing transmembrane
protein 1) and BDNF.
In contrast, BTG2, the only anti-proliferation gene included here
[28], demonstrated signiﬁcantly increased expression up to ~5 fold
in HHIP shRNA-infected cells. For BIRC5, BDNF, FGF2 and BTG2, the
effect of HHIP knock-down on expression levels was validated in pri-
mary human bronchial epithelial cell lines (NHBE, Lonza) (Fig. 3B).
We attempted to validate protein level changes for three of our dif-
ferentially expressed genes, CCND1, TGM2 and BIRC5; we detected
protein level reductions in Beas-2B cells infected with HHIP shRNAs
for all three of these genes (Fig. 3C).
2.6. HHIP target genes are also differentially expressed in human COPD
lung tissues
We have previously shown that HHIP expression is reduced
in human COPD compared to control lung tissues [12]. To provideadditional evidence that HHIP target genes associated with cell prolif-
eration or ECM are relevant to COPD pathogenesis, we examined ex-
pression of 11 selected HHIP target genes in human COPD and control
lung tissues from the Lung Tissue Research Consortium (LTRC) by
RT-PCR to determine whether COPD is associated with expression
patterns similar to those seen following knock-down of HHIP in vitro.
Among-ECM related genes, PI3 showed a trend of increased expres-
sion in human COPD lung tissues compared to control tissues from
ex-smokers (p = 0.08); while WNT5B and SDC1 demonstrated signiﬁ-
cantly decreased expression in human COPD lung tissues (Fig. 4A,
p b 0.01, unpaired t test), recapitulating the pattern seen after HHIP
knock-down in cell culture. Among genes associated with cell growth,
CREB3L2, CCND1, ATF5 and LETM1 showed signiﬁcantly decreased ex-
pression (p b 0.05) and TGM2 showed a trend for decreased expression
(p = 0.052) in human COPD lung tissues compared with controls,
again recapitulating the effect of HHIP knock-down in cell culture.
However, for RECK (Fig. 4A, which was statistically signiﬁcant in
the direction opposite from our expectation based on RNAi studies),
G0S2 and BTG2 (data not shown), the expression pattern in our set
of COPD and control lung tissues did not conﬁrm the statistically sig-
niﬁcant changes observed after HHIP knock-down. Overall, these data
suggest that most of the novel Hhip targets identiﬁed in this study
may participate in human COPD pathogenesis.
Furthermore, we measured gene expression of Sonic Hedgehog
pathway members including SHH, PTCH1, GLI1, GLI2 and GLI3 in
human lung tissue samples that contain mixed cell populations.
There are relatively low expression levels of GLI1 and SHH in human
lung tissues, consistent with previous reports [29]. Compared to
samples from control smokers, we detected signiﬁcantly decreased
expression of SHH, PTCH1, GLI1, GLI2, and GLI3 (Supplemental Fig. 3)
in lung tissue samples from COPD subjects. Hence, the canonical
Hedgehog pathway might participate in COPD pathogenesis in other
cell types (or in epithelial cells after cellular injury) [29].
2.7. Network building based on Beas-2B cell microarray analysis
To understand the relationships between the genes found to be
regulated by HHIP, we performed data mining and curation using the
Predictive Networks web application [30] with default parameters.
Top differentially expressed genes (n = 442) with p-adjusted b0.05
found using iSVA after HHIP silencing were used as seeds for network
analysis. The resulting network includes 7489 connections among
1958 genes, including 87 genes that were differentially expressed by
HHIP shRNAs (highlighted in red circles in Supplemental Fig. 4). In
this network, gene clusters centered on some validated target genes
such as CCND1, SERPING1, and RECK were observed (Supplemental
Fig. 4).
Next, we asked whether the network showed interconnections
between HHIP target genes associated with cell growth and extracel-
lular matrix. Within this network analysis model, we found several
primary and secondary connections between the 18 validated cell
proliferation and extracellular matrix genes (Fig. 5); in addition, 26
additional differentially expressed genes showed direct interactions
with the 18 validated genes, and 220 differentially expressed genes
are within two degrees of separation from the validated genes. The
large number of connections observed between differentially expressed
genes suggests that the genes which have differential expression after
HHIP knock-down may have shared biological functions.
To estimate the statistical signiﬁcance of the number of connec-
tions between ECM and proliferation genes seen in our network, we
generated 10,000 gene sets of the same size as in our validated gene
set, drawing randomly from the genome; for each, we generated
literature-based networks using the network reconstruction protocol
described previously. While the number of connections between ECM
genes in our validated gene set is not signiﬁcant (p = 0.4, Supple-
mental Fig. 5A left panel), the number of connections between cell
Fig. 3. Genes associated with cell growth that demonstrated signiﬁcant differential expression (p b 0.05) after HHIP-knock-down in Beas-2B (A) or normal human bronchial epi-
thelial cells (NHBE) (B), as measured by TaqMan assay-based RT-PCR. Three different HHIP-targeted shRNAs were used for knock-down. Relative expression values were calculated
as described in Materials and method and represent means ± standard errors from two (A) or three (B) replicates for each hairpin. P values in Fig. 3B are calculated based on two
biological replicates and one is represented here. C. Expression of CCND1, TGM2 and BIRC5 in Beas-2B cells infected with HHIP-targeted or non-target (NT) control shRNA, as
detected by western blot. α-actin was used as loading control. Band density was quantiﬁed using Image J and then normalized to α-actin control.
267X. Zhou et al. / Genomics 101 (2013) 263–272proliferation genes is signiﬁcantly greater than expected by chance
(p b 0.01, Supplemental Fig. 5A middle panel).
Given the representation of ECM and proliferation genes in the
validated gene set, the enrichment of connections between these
genes may not be surprising. To test the statistical signiﬁcance of
the observed associations, we constructed 10,000 random networks
consisting of only ECM genes (N = 7) and proliferation genes
(N = 11). Based on this analysis, the connections within the ECM
gene subset, and within the cell proliferation gene subset, compared
to the random networks are not signiﬁcant (p = 0.67 and 0.09,Fig. 4. Expression of HHIP target genes associated with ECM (A) or cell growth (B) were
values were calculated as described in Materials and method and represent means ± stan
non-signiﬁcant.respectively). However, the number of observed connections be-
tween ECM genes and cell proliferation genes is signiﬁcantly greater
than we would expect by chance (p = 0.0035, Supplemental Fig. 5B),
suggesting that we may have discovered important new connections
between the ECM and proliferative processes in the cell. Using GO
annotations, 12 of the 18 validated genes are connected to cell prolif-
eration genes, and 9 are connected to at least one extracellular matrix
modiﬁcation gene. For example LETM1 (a cell proliferation gene) has
connections with MMP2 and MMP9, which are inhibited by RECK
(extracellular matrix genes).measured in human COPD and control lung tissues by RT-PCR. Relative expression
dard errors for COPD (n = 15) and Controls (n = 18). **p b 0.01 and *p b 0.05. n.s.,
Fig. 5. Network analysis of validated HHIP targets related to ECM and cell proliferation (highlighted by pink circles). Edge colors represent sources of the interaction (brown: Path-
way Commons, purple: functional interaction, blue: PubMed abstract, teal: Medline abstract, red: manual curation based on recently published literature) and node colors represent
the level of differential expression (red: highly differential, gray: no expression change.) Thickened edges connect pairs of differentially expressed genes.
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Genetic variants near HHIP have been consistently associated with
COPD susceptibility, and a functional variant inﬂuencing HHIP ex-
pression has been previously reported by our group [12]. Based on
these genetic association results, we hypothesized that HHIP would
inﬂuence COPD susceptibility through the Hedgehog pathway. The
Hedgehog (HH) signaling pathway is critical for organogenesis and
carcinogenesis [22].
Vertebrate organisms have three types of Hedgehog ligands: Sonic
Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog
(DHH). Binding of the Hedgehog ligand to its membrane receptor,
protein patched homolog 1 (PTCH1), triggers a series of cytoplasmic
signaling cascades and eventually activates transcription factors
GLI1, GLI2, and GLI3 [22]. HHIP, through its extracellular domain,
binds to all three types of HH ligands and inhibits HH signaling
[13,31,32].
In adults, detectable expression of HHIP was previously found
in both whole lung [12] and primary bronchial epithelial cells
(unpublished data). However, in our study, SHHwas barely detectable
in both Beas-2B and primary small airway epithelial cells. Moreover,
induced expression of PTCH1 and GLI1 are usually regarded as hall-
marks for the activation of the canonical Hedgehog pathway. None-
theless, no signiﬁcant expression changes of PTCH1 or GLI3 were
observed after HHIP knock-down, and GLI1 demonstrated increased
but still relatively low expression in Beas-2B cells with HHIP silencing.Only a subset of the HHIP targets identiﬁed here, such as TULP3 [33]
and CCND1 [23,33], are known targets of the Hedgehog pathway.
Based on these observations, it is unlikely that the canonical Hedgehog
pathway can explain all of the gene expression changes that we ob-
served in the Beas-2B cells treated with HHIP shRNAs. However,
given the complexity of the Hedgehog pathway, which includes both
ligand-dependent and ligand-independent activation [34,35] mecha-
nisms,more comprehensive evaluations are needed to addresswhether
Hedgehog signaling regulates expression of these novel HHIP targets
in human bronchial epithelial cells through non-canonical pathways.
Interestingly, when we assessed the canonical Hedgehog pathway in
human COPD lung tissues by qPCR targeting themajor pathway compo-
nents: SHH, PTCH1, GLI1, GLI2 and GLI3 (Supplemental Fig. 3), we
detected overall reduced pathway activity in COPD subjects compared
to controls. This may indicate a plausible role of the Hedgehog pathway
in human COPD. Based on the gene expression levels that we observed
in lung epithelial cell lines, we speculate that the involvement of the
Hedgehog pathway in COPD could be mediated in other cell types or
in lung epithelial cells only after cellular injury.
We found 296 geneswith signiﬁcant alterations in their expression
levels after HHIP silencing in Beas-2B cells. The occurrence of the
RAB4B gene (within the chromosome 19 COPD GWAS region) and
the observed enrichment of other COPD genetic association signals
which do not reach conventional levels of genome-wide signiﬁcance
suggest that SNPs within other members of this set of differentially
expressed genes could inﬂuence COPD susceptibility. Further work
269X. Zhou et al. / Genomics 101 (2013) 263–272to clarifywhich of these genes are associatedwith COPD in larger sam-
ple sizes and other study designs (e.g., eQTL analysis) could lead to
the identiﬁcation of novel genes for COPD susceptibility that interact
with HHIP.
Our study provides some helpful insights regarding the mecha-
nisms through which HHIPmay affect COPD susceptibility. In particu-
lar, the results shown here suggest that HHIP may inﬂuence an
individual's susceptibility to smoke-induced COPD by regulating
extracellular matrix (ECM) remodeling and cell growth pathways.
The expression levels of multiple extracellular matrix-related genes
were signiﬁcantly changed byHHIP shRNAs based on gene enrichment
analysis.
Additionally, a subset of these ECM-related genes also demon-
strated signiﬁcant differential expression in human COPD lung sam-
ples. For example, SDC1 expression was signiﬁcantly decreased in
both Beas-2B cells with HHIP silencing and in human COPD lungs.
SDC1 encodes a heparan sulfate proteoglycans transmembrane pro-
tein that is an important component of ECM as well as regulating
matrix assembly [36]. It also protects lung epithelial cells from injury
by removing C-X-C chemokines during inﬂammation [37].
Another differentially expressed gene, PI3/Elaﬁn, is an inhibitor
for neutrophil elastase, while RECK (a membrane-bound protein)
can exert inhibitory effects on the transcription, synthesis, activation,
and activity of MMPs, including MMP2, MMP7, and MMP9 [38–41]. It
is not entirely surprising to detect signiﬁcant expression changes
of RECK in human COPD lungs given its crucial roles in regulating
the activities of MMPs, and the importance of imbalance between
proteinases and anti-proteinases in human lungs contributing to the
pathogenesis of COPD/emphysema.
However, how HHIP affects expression of ECM-related genes
requires further mechanistic investigations. It is possible that HHIP,
as a cellular membrane protein [13], directly cross-talks with other
cellular transmembrane proteins such as Syndecan-1 to facilitate its
anti-inﬂammatory and extracellular matrix functions.
Among the most signiﬁcant differentially expressed genes after
HHIP silencing found by microarray analysis, we used RT-PCR to con-
ﬁrm reductions in expression of several cell cycle and proliferation-
related genes, G0S2, CCND1, FGF2, BIRC5 and TGM2, as well as in-
creased expression of an anti-proliferation gene, BTG2. This apparent
regulation by HHIP of cell growth genes in Beas-2B cells (Fig. 3) is
consistent with previous ﬁndings in HHIP conditional transgenic
mice that over-expression of HHIP lacking the transmembrane do-
main led to hyper-proliferation of small intestine epithelium [42].
Moreover, GLI2 has been reported to regulate lung epithelial
growth by modulating Cyclin expression including Cyclin D1 [23],
consistent with our ﬁndings of decreased expression of CCND1
and GLI2 (Supplemental Fig. 1B) with HHIP shRNAs. Given that the
HHIP gene locus was also associated with height in multiple popula-
tions [43], it is conceivable that HHIP may regulate cell growth and
proliferation.
In addition, apoptosis has been implicated in COPD pathogenesis
[44]. HHIP target genes FGF2 [45] and ATF5 [27] positively regulate
expression of BCL2 anti-apoptotic protein, which showed decreased
expression accompanied by increased pro-apoptotic protein BAX
expression in cigarette smoke (CS) induced cell death in vitro [46]
and in vivo [47]. Additionally, BIRC5, a potent anti-apoptosis protein,
interferes with cell death through caspase-dependent and indepen-
dent mechanisms [48]. Hence, gene expression changes including
decreased expression of FGF2, ATF5 and BIRC5 in HHIP-depleted
cells may contribute to smoke-induced lung injury due to enhanced
cell apoptosis.
When we used a recently developed network modeling approach
to analyze our microarray results, we found not only that most of our
validated hits are clustered in this “predictive network” (Supplemental
Fig. 4) but also that there are direct or indirect connections (0–1
connectors) between our validated cell proliferation and ECM-relatedgenes (Fig. 5), suggesting that the genes in these two pathways that
are perturbed by HHIP knock-down may have shared biological func-
tions. This network analysis included a variety of genes which have
been previously implicated in COPD pathogenesis, but which were not
directly identiﬁed by our gene expression analysis after HHIP silencing.
For example, EGR1 was identiﬁed as a key differentially expressed gene
in a microarray gene expression analysis of human COPD and normal
lung tissues [49]. Multiple members of the integrin family also appear
in this HHIP network, including ITGAV, which has been implicated
in TGF-β activation [50]. Thus, the network identiﬁed after HHIP deple-
tion could relate directly to previously reported components of COPD
pathobiology.
Nonetheless, there are some limitations related to our study. First,
the gene expression changes induced by HHIP shRNAs may result
from both primary effects of genetic perturbation of HHIP expression
or the downstream signaling events related to these primary effects.
Second, only a subset of the differentially expressed genes identiﬁed
by microarray analysis were validated by RT-PCR; further work will
be required to determine whether these inconsistencies represent
false-positivemicroarray results or false-negative validation attempts.
Finally, it is possible that the mixed cell population in whole lung
homogenates from COPD subjects, phenotypic heterogeneity within
COPD subjects, and the moderate sample size of our COPD case and
control lung tissue population accounts for our ability to conﬁrm
some, but not all, of the gene expression differences that we observed
in cell-based gene expression analysis.
4. Conclusion
In summary, we have applied transcriptome proﬁling in human
bronchial epithelial cell lines that were silenced with HHIP shRNAs
to identify novel targets of the HHIP gene that may participate in
the pathogenesis of human COPD. Our whole-transcriptome analysis
suggests novel pathways by which HHIP may affect COPD pathogen-
esis. Further functional validation of the roles of these intriguing tar-
gets of HHIP in smoke-induced murine COPD models is warranted.
5. Materials and methods
5.1. Cell culture and human lung tissues
Human Beas-2B bronchial epithelial cells (#CRL-9609) were
purchased from ATCC and cultured in complete DMEM medium
supplemented with 10% fetal bovine serum, penicillin (50 units/ml),
streptomycin (50 μg/ml) and gentamicin (10 μg/ml). Normal Human
Bronchial Epithelial cells (NHBE) from healthy non-smoker donors
and medium for culturing NHBE were purchased from Lifeline, Inc.
Human lung tissue samples from 15 COPD patients (FEV1 b 80%)
and 18 control subjects with normal lung function were obtained
from the NHLBI Lung Tissue Research Consortium (LTRC), a national
biorepository of lung tissues.
5.2. Gene silencing of HHIP by RNA interference in Beas-2B cells
Four individual HHIP-targeting shRNAs and one non-targeting
scrambled shRNA (Open Biosystems, Thermo Scientiﬁc) were
transfected into 293T cells for packaging into lentivirus particles.
Beas-2B cells were infected with lentivirus-based shRNAs using stan-
dard methods [49]. Approximately 24 h post-infection, puromycin
was added at 1.5 μg/ml for 3–4 days to select for successfully infected
cells before RNA and protein extraction.
5.3. Detection of differential gene expression
Total RNA from Beas-2B cells was extracted using the RNeasy Mini
Kit (Qiagen, Germantown, MD). Differential gene expression detected
270 X. Zhou et al. / Genomics 101 (2013) 263–272by gene expression microarrays was validated by real-time PCR
with gene-speciﬁc primers on an ABI 7900 HT instrument (Applied
Biosystems, Foster City, CA), using SYBR Green for detection. If statis-
tically signiﬁcant expression changes were conﬁrmed, RT-PCR was
repeated using TaqMan probes for detection. Relative gene expres-
sion was calculated based on the standard 2−ΔΔCT method, using
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) and control
cells as references. TBP (TATA box binding protein) was also used as
a reference gene in all TaqMan based RT-PCR validations. Primer
and probe sequences are listed in the Supplemental Tables 1 and 2.
5.4. Network analysis
Unbiased, automated literature mining was performed on the dif-
ferentially expressed genes (adjusted p-value b 0.05) using the Predic-
tive Networks application [30]. We gathered gene pairs representing
genetic interactions, regulatory functions, and pathways collected
from PubMed and Medline abstracts and other published sources.
Networks were visualized by Cystoscape (http://www.cytoscape.org).
A sub-network centered around the RT-PCR validated genes was pro-
duced to illustrate connections between the differentially expressed
genes and cell proliferation/survival and extracellular matrix functions.
First, only validated genes and their interactionswere selected. Then, all
non-differentially expressed genes with one interacting partner were
removed, retaining only genes that connect to differentially expressed
genes.
To estimate the statistical signiﬁcance of the number of connections
to ECM and proliferation genes seen in our network, we generated
10,000 random gene sets of the same size (18) as in our validated
gene sets and used them to generate literature-based networks using
the network reconstruction protocol described previously. We then
counted the total number of connections in that network, the number
of connections between ECM genes (deﬁned by GO:0005576 and
GO:0005615 classes), the number of connections between cell prolifer-
ation genes (deﬁned by GO:0008283), and the number of connections
between ECM and cell proliferation genes (excluding internal connec-
tions among ECM genes and connections among proliferation genes)
for each of the randomnetworks. The empirical p-values for enrichment
are calculated by taking the fraction of random networks having
a greater number of connections than the observed values. This was
repeated with random gene sets generated by using the same numbers
of ECM genes (7) and proliferation genes (11) as in the validated
gene set.
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